SAN DIEGO, CA, Persephone Biosciences today announced that it has closed a $15 million seed financing round.
Persephone Biosciences, a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society's BrightEdge Fund, Pioneer Fund, and ZhenFund among others.
Persephone Biosciences is pioneering the use of synthetic biology for the development of microbial products that impact patient and infant health. Persephone is building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about